secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxcyte, Inc. (PCVX)
CIK:        0001649094
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001649094-25-000096
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxcyte Q2 net loss $166.6M, cash $2.83B; VAX-31 Phase 3 on track for Q4 start
------------------------------------------------------------------------------

- Net loss $166.6M for Q2 2025 vs $128.7M a year ago; R&D expenses $194.2M, up from $131.5M.
- Cash, cash equivalents and investments $2.83B as of June 30, 2025; cash runway extended to mid-2028.
- VAX-31 adult pivotal non-inferiority study to begin Q4 2025 with topline data expected in 2026.
- VAX-31 infant Phase 2 modified: new optimized dose arm added, low dose arm discontinued; data by H1 2027.
- Early pipeline streamlined: paused VAX-A1 and VAX-GI, discontinued VAX-PG due to insufficient efficacy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649094/000164909425000096/0001649094-25-000096-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649094/000164909425000096/pcvx-20250806.htm
  HTML page:      https://secwatch.observer/filing/0001649094-25-000096

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer